Nab-Paclitaxel ± CC-486 as Second-Line Treatment of Advanced NSCLC: Results from the ABOUND.2L+Study

被引：0

作者：

Morgensztern, D. ^{[1
]}

Cobo Dols, M. ^{[2
]}

Ponce Aix, S. ^{[3
]}

Postmus, P. E. ^{[4
]}

Bennouna, J. ^{[5
]}

Fischer, J. ^{[6
]}

Vidal, O. ^{[7
]}

Stewart, D. ^{[8
]}

Fasola, G. ^{[9
]}

Weaver, J. ^{[10
]}

Wolfsteiner, M. ^{[11
]}

Ong, T. J. ^{[10
]}

Govindan, R. ^{[1
]}

机构：

[1] Washington Univ, Sch Med, St Louis, MO USA

[2] Hosp Reg Univ Carlos Haya, Gen Hosp, Malaga, Spain

[3] Unidad Invest Clin Canc Pulmon H12O Cnio, Madrid, Spain

[4] Clatterbridge Canc Ctr, Liverpool, Merseyside, England

[5] Ctr Rene Gauducheau, Ctr Lutte Canc Nantes Atlantique, Nantes, Loire Atlantiqu, France

[6] Lungenklin Lowenstein, Lowenstein, Baden Wurttembe, Germany

[7] Univ Politecn La Fe, Valencia, Spain

[8] Ottawa Hosp, Ottawa, ON, Canada

[9] Univ Hosp Santa Maria Della Misericordia, Udine, Italy

[10] Celgene Corp, Summit, NJ USA

[11] Pra Hlth Sci, Lenexa, KS USA

来源：

关键词：

nab-paclitaxel; Second-line; CC-486;

D O I：

10.1016/j.jtho.2017.09.460

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA 03.01

引用

页码：S1806 / S1807

页数：2